Wegovy Can Treat a Dangerous Liver Disease, Study Finds
New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease.The study, published Wednesday in the New England Journal of Medicine, included 800 adults with a severe form of liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH.People develop MASH after fat builds up in the liver, which can lead to inflammation, cell damage and scarring.
The condition, which affects nearly 15 million adults in the United States alone, is one of the most common reasons for liver transplants nationwide.It is closely linked with obesity and Type 2 diabetes, both of which are also on the rise.Novo Nordisk, the company that makes Ozempic and Wegovy, sponsored the study, as is common with clinical trials.
The Phase 3 trial included people with moderate or advanced levels of liver scarring.After 72 weeks, nearly 63 percent of those who received semaglutide injections and around 34 percent of those on placebo shots saw the fat and inflammation in their livers clear up without any worsening of their liver scarring.And nearly 37 percent of those who took semaglutide had less scar tissue than they started the trial with, with no worse inflammation or fat buildup.That was compared to around 22 percent in the placebo group.Inflammation and fat in the liver are the major factors that cause liver scarring in people with MASH, which can then lead to liver failure, said Dr.
Vandana Khungar, a hepatologist at Yale New Haven Hospital who was not involved with the study.Patients may need a liver transplant, or can die from the disease.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access.
If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscr...